Reference health
B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
33/33 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 33 checked references that resolve
resolves10.1016/j.msard.2015.04.006
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
resolves10.1016/j.pneurobio.2016.02.001
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research
resolves10.1002/eji.1830010406
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
resolves10.1002/eji.1830030506
<i>In vivo and in vitro</i> immunological cross‐reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis
resolves10.1016/0019-2791(76)90344-X
Molecular requirements involved in suppression of eae by synthetic basic copolymers of amino acids
resolves10.1073/pnas.88.21.9528
Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.
resolves10.1001/jamaneurol.2014.1472
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis
resolves10.2165/11591110-000000000-00000
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
resolves10.1016/j.clim.2014.02.014
Identification of a B cell-dependent subpopulation of multiple sclerosis by measurements of brain-reactive B cells in the blood
resolves10.1186/s40478-014-0138-2
Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood
resolves10.1038/srep14265
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
resolves10.3389/fneur.2018.01150
The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
resolves10.1097/WCO.0000000000000203
Novel and imminently emerging treatments in relapsing–remitting multiple sclerosis
resolves10.1177/1352458516687402
Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS
resolves10.1136/jnnp-2016-313976
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
resolves10.1001/jama.2018.20588
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
resolves10.1212/NXI.0000000000000698
Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
resolves10.1080/23744235.2016.1269190
Positive predictive value of ELISpot in BAL and pleural fluid from patients with suspected pulmonary tuberculosis
resolves10.1371/journal.pone.0197825
Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis
resolves10.1002/9780470987810.ch9
Validating Reference Samples for Comparison in a Regulated ELISPOT Assay
resolves10.1073/pnas.2011249117
Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients
resolves10.1016/j.clim.2019.108297
JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response
resolves10.1212/WNL.0000000000007032
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
resolves10.1177/1352458519885613
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
resolves10.2217/pgs.14.26
Comparative Pharmacogenetics of Multiple Sclerosis: IFN-β Versus Glatiramer Acetate
resolves10.1016/j.autrev.2013.10.012
Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature
resolves10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
resolves10.1093/brain/awm038
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
resolves10.1093/brain/awr182
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
The 1 reference without a DOI — listed, not checked
no DOI — not checkedCoyle PK. Pharmacogenetic biomarkers to predict treatment response in multiple sclerosis: current and future perspectives. Mult Scler Int 2017;2017:6198530.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1212/nxi.0000000000000980"><img src="https://citestamp.com/citestamped/10.1212/nxi.0000000000000980/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1212/nxi.0000000000000980)